How they differ
Semaglutide and tirzepatide are different molecules acting on different pathways — semaglutide as a GLP-1 receptor agonist, tirzepatide on dual receptors. That's a real clinical distinction, and patients increasingly arrive having heard of both. But for a medspa's business decision, the clinical difference matters less than two things they have in common.
What they share: the compliance burden
Both sit in an area of significant, evolving regulatory scrutiny, and both raise the same hard questions around sourcing, compounding, supervision, and appropriate medical evaluation. The compounding and sourcing of these preparations — where they come from, how they're prepared, through what channels — is exactly the issue drawing regulatory attention, and it applies identically to either molecule. So the idea that one is "easier" to offer than the other from a compliance standpoint is mostly an illusion; the burden is the same, and it's substantial.
The owner's actual decision
Because the compliance burden is shared, the offering decision comes down to demand, positioning, and footing rather than a clinical preference. Which does your patient base ask for? Where can you source compliantly? How do you want to position your weight-management service? Get the compliance foundation right — legitimate sourcing, proper supervision and evaluation, structured with counsel — and the product choice becomes a demand-and-positioning question, not the crux. Get it wrong, and which molecule you chose is irrelevant because the whole offering is exposed.
What to do
- Treat both as carrying the same significant compliance burden — sourcing, compounding, supervision, evaluation — rather than assuming one is simpler.
- Get the compliance foundation right first with counsel and your medical director: legitimate sourcing, proper supervision, appropriate medical evaluation.
- Choose based on demand and positioning, not a clinical "winner," since the regulatory burden is shared.
- Watch the evolving regulatory landscape closely, because the scrutiny on sourcing and compounding affects both equally.
Frequently asked questions
What's the difference between semaglutide and tirzepatide?
They're different molecules in the GLP-1 weight-management space — semaglutide is a GLP-1 receptor agonist, tirzepatide acts on dual pathways. Clinically they differ in mechanism; for a medspa, the offering decision involves demand, positioning, and especially the sourcing, compounding, and supervision compliance that applies to both. This is general education, not medical advice.
Can a medspa offer these weight-management drugs?
Where permitted and done compliantly — with appropriate medical evaluation, supervision, and legitimate sourcing — some practices offer GLP-1-class weight-management services. The sourcing and compounding of these products is an area of significant regulatory scrutiny that must be handled carefully with counsel and your medical director.
Which should I offer?
There's no clear medspa 'winner' — both carry the same compliance burden around sourcing and supervision. The decision is driven more by patient demand, your positioning, and what you can offer on solid regulatory footing than by a clinical preference. Get the compliance right first; the product choice follows.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo Join the owners who run ahead of the industry. Cancel anytime, one click.
